Core Viewpoint - The company has announced a change in its continuous supervision sponsor representative due to the work relocation of the previous representative, ensuring continuity in supervision duties [1][2]. Group 1 - The company received a letter from Huaxing Securities regarding the replacement of the continuous supervision sponsor representative [1]. - Wang Chumei, the previous representative, will be replaced by Guan Yuxia to maintain the continuity of supervision work [1]. - The new supervision representatives are Shen Ying and Guan Yuxia, with the supervision period continuing until the end of obligations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange [1]. Group 2 - The company's board expressed gratitude for the work done by Wang Chumei during her tenure as the continuous supervision representative [2]. Group 3 - Guan Yuxia holds a master's degree, is a non-practicing member of the Chinese Institute of Certified Public Accountants, and has legal qualifications [4]. - Guan Yuxia is currently a senior manager in the investment banking division of Huaxing Securities and has participated in various IPO projects, including the company's stock issuance [4].

证券代码：300972 证券简称：万辰集团 公告编号：2025-038 福建万辰生物科技集团股份有限公司 官玉霞女士简历 官玉霞女士，保荐代表人，硕士研究生学历，具有中国注册会计师（非执业 会员）与法律职业资格，现任华兴证券投资银行事业部高级经理，曾参与永林电 子 IPO、万辰集团向特定对象发行股票项目，在保荐业务执业过程中严格遵守《证 券发行上市保荐业务管理办法》等相关规定，执业记录良好。 本次保荐代表人变更不影响华兴证券对公司的持续督导工作。本次保荐代表 人变更后，公司持续督导保荐代表人为沈颖女士、官玉霞女士，持续督导期至中 国证券监督管理委员会和深圳证券交易所规定的持续督导义务结束为止。 公司董事会对王楚媚女士在公司持续督导期间所做的工作表示衷心感谢！ 特此公告。 福建万辰生物科技集团股份有限公司 董事会 2025 年 5 月 30 日 附件： 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 福建万辰生物科技集团股份有限公司（以下简称"公司"）于近日收到华兴 证券有限公司（以下简称"华兴证券"）出具的《华兴证券有限公司关 ...

Group 1 - The chairman of Wancheng Group, Wang Jiankun, has had his detention lifted, allowing him to resume his duties, which is expected to stabilize the company's operations [1] - During Wang's detention, Wancheng Group's stock price increased significantly, rising from 94.99 yuan per share to a peak of 156.85 yuan per share, marking a gain of over 65% [1] - Wancheng Group reported a total of over 15,000 signed stores by the end of Q1, with a rapid opening pace, particularly in its "Haoxianglai" brand, which has over 10,000 stores [2][3] Group 2 - Despite the rapid expansion, Wancheng Group's revenue for the last year was 32.3 billion yuan, significantly lower than its main competitor, Mingming Hen Mang, which reported 39.3 billion yuan [2] - Wancheng Group's net profit for the last year was approximately 294 million yuan, while Mingming Hen Mang's adjusted net profit reached 913 million yuan, highlighting a substantial profitability gap [2] - In Q1, Wancheng Group achieved a revenue of 10.82 billion yuan, a year-on-year increase of 124.02%, and a net profit of approximately 215 million yuan, reflecting a staggering growth of 3344.13% [5] Group 3 - The company aims to enhance its supply chain efficiency and profitability through a value chain restructuring mechanism that includes direct procurement and centralized pricing [6] - Wancheng Group plans to continue investing in its supply chain, logistics, brand development, and digital capabilities to improve profit margins and operational efficiency [6] - The company acknowledges the need to maintain growth momentum in the face of a slowing store opening pace and is focused on optimizing its operational strategies [5][6]

今日导读 1. 5月26日，商务部、国家发展改革委等8部门发布《加快数智供应链发展专项行动计划》， 明确在农业、制造业、批发业、零售业等重点领域加快数智供应链发展，推动降低全社会物 流成本，培育一批数智供应链领军企业和供应链中心城市。 2. 美团港交所发布财报，第一季度营收865.6亿元人民币，同比增18.1%；调整后净利润 109.5亿元人民币，同比增长46.2%。 3. 5月26日，针对"网传玄戒O1是向Arm定制的芯片"相关提问，小米公司表示："不是。这 完全是谣言，玄戒O1不是向Arm定制的，研发过程中，也没有采用Arm CSS服务。" 宏观消息 1、 据新华社5月26日消息，中共中央办公厅、国务院办公厅印发《关于完善中国特色现代企业制度的 意见》。意见从坚持和加强党的领导、完善公司治理结构、提升企业科学管理水平、健全企业激励创 新制度、建立健全企业社会责任与企业文化体系、优化企业综合监管和服务体系等方面作出全面系统 部署，重在以制度创新赋能企业发展，进一步释放微观主体活力，培育更富活力、更具韧性、更有竞 争力的现代企业，为以中国式现代化全面推进强国建设、民族复兴伟业提供有力支撑。 2、5月26日，商 ...

Core Viewpoint - The company is experiencing strong operational performance with significant revenue and profit growth, and is well-positioned to expand its discount supermarket presence, leveraging its scale advantages in the snack retail sector [1][2]. Group 1: Financial Performance - In Q1, the company achieved a revenue of 10.821 billion yuan, representing a year-on-year increase of 124.02% [1] - The net profit attributable to shareholders was 215 million yuan, a staggering year-on-year increase of 3,344.13% [1] - The net profit from the snack retail business, after excluding share-based payment expenses, was 412 million yuan, with a net profit margin of 3.85%, up by 1.36 percentage points year-on-year [1] Group 2: Expansion and Market Position - Q2 and Q3 are expected to be peak seasons for store openings, indicating a potential acceleration in expansion [1] - The company has launched an employee stock incentive plan to enhance employee motivation, which may further support growth [1] - The number of discount supermarkets has been increasing since the end of last year, with both snack retail enterprises and regional brands transforming traditional supermarkets into discount formats [1] Group 3: Future Projections - The company is projected to maintain high revenue growth, with expected revenues of 55.132 billion, 67.039 billion, and 79.289 billion yuan for 2025-2027, reflecting year-on-year growth rates of 70.53%, 21.60%, and 18.27% respectively [2] - The net profit attributable to shareholders is expected to reach 734 million, 984 million, and 1.196 billion yuan for the same period, with year-on-year growth rates of 149.95%, 34.10%, and 21.61% respectively [2] - The company is anticipated to benefit from scale effects, leading to continuous improvement in profitability [2]

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

Company Overview - Wanchen Group, known as the "first stock of snack retail," announced that former chairman Wang Jiankun has resumed his duties after the National Supervisory Commission lifted the detention measures against him [2][4] - Wang Jiankun has been the chairman since December 2013, and his family members, including his son Wang Zeneng and sister Wang Liqing, are significant stakeholders in the company [4] Business Development - Founded in 2011, Wanchen Group initially focused on edible fungi but entered the snack retail market in August 2022 with the launch of the "Luxiaochan" brand [5] - The company has rapidly expanded its snack retail presence through joint ventures and acquisitions, rebranding several acquired brands under "Haoxianglai" [5] Market Position - As of the end of 2024, Wanchen Group operates 14,196 stores, closely competing with Mingming Hen Mang Group, which has 14,394 stores [5] - Wanchen Group is the only publicly listed company in the snack retail sector, while Mingming Hen Mang Group has also filed for an IPO [5] Financial Performance - For the year 2024, Wanchen Group reported revenue of 32.33 billion yuan, a year-on-year increase of 247.86%, and a net profit of 294 million yuan, up 453.95% [5] - In comparison, Mingming Hen Mang Group achieved revenue of 39.34 billion yuan, with a net profit of 829 million yuan, reflecting a year-on-year growth of 280.28% [5]

Group 1 - The A-share food and beverage sector experienced a surge, with Jiayuan Health hitting the daily limit, and Miaokelando rising over 6% [1] - Other companies such as Chengde Lululemon, Wancheng Group, and Liziyuan also saw significant gains [1]

Core Viewpoint - Wanchen Group announced that the detention measures against Chairman Wang Jiankun have been lifted, allowing him to resume his duties as chairman of the company [1] Group 1 - The company received notification from Wang Jiankun's family that a national supervisory committee has lifted the detention measures [1] - Wang Jiankun is now able to perform his responsibilities as chairman normally [1] - The company's production and operational situation remains normal following this development [1] Group 2 - Wang Liqing, the director and general manager, will no longer act on behalf of Wang Jiankun in his role as chairman and committee member [1]

证券代码：300972 证券简称：万辰集团 公告编号：2025-037 福建万辰生物科技集团股份有限公司 关于公司董事长解除留置的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告 福建万辰生物科技集团股份有限公司 董事会 2025 年 5 月 26 日 福建万辰生物科技集团股份有限公司（以下简称"公司"）于 2025 年 3 月 3 日披露了《关于公司重大事项的公告》（公告编号：2025-006）。 近日，公司收到王健坤先生家属的通知，国家某监察委员会已解除对王健坤 先生的留置措施，目前王健坤先生已能正常履行公司董事长职责，公司生产经营 情况正常，董事兼总经理王丽卿女士不再代为履行公司董事长及董事会专门委员 会委员等相关职责。 公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》及 巨潮资讯网（www.cninfo.com.cn），公司发布的信息均以在上述媒体披露的信 息为准。敬请广大投资者理性投资，注意投资风险。 ...